ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "Clinical Response"

  • Abstract Number: 912 • 2014 ACR/ARHP Annual Meeting

    A Consensus Hybrid Definition Using a Conjoint Analysis Is the Proposed As Response Criteria for Minimal and Moderate Improvement for Adult Polymyositis and Dermatomyositis Clincal Trials

    Rohit Aggarwal1, Lisa G. Rider2, Nicolino Ruperto3, Nastaran Bayat2, Brian Erman4, Brian M. Feldman5, Adam M. Huber6, Chester V. Oddis7, Ingrid E. Lundberg8, Anthony A. Amato, MD9,10, Robert G. Cooper, MD, FRCP11, Hector Chinoy12, Maryam Dastmalchi13, David Fiorentino14, David Isenberg15, James D. Katz16, Andrew L. Mammen17, Marianne de Visser18, Steven R. Ytterberg19, Katalin Danko20, Luca Villa21, Mariangela Rinaldi21, Howard Rockette22, Peter A. Lachenbruch2, Frederick W. Miller2 and Jiri Vencovsky, MD, DSc23, 1Medicine, University of Pittsburgh, Pittsburgh, PA, 2Environmental Autoimmunity Group, NIEHS, NIH, Bethesda, MD, 3Pediatria II,, Istituto Giannina Gaslini, Genoa, Italy, 4Social and Scientific Systems, Inc., Durham, NC, 5Rheumatology, The Hospital for Sick Children, Toronto, ON, Canada, 6IWK Health Centre, Halifax, NS, Canada, 7Rheum/Clinical Immunology, University of Pittsburgh, Pittsburgh, PA, 8Rheumatology Unit, Karolinska University Hospital, Solna, Karolinska Institutet, Stockholm, Sweden, 9Brigham and Women's Hospital and Harvard Medical School, Boston, MA, 10Department of Neurology, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA, 11MRC/ARUK Institute of Ageing and Chronic Disease, University of Liverpool, Liverpool, United Kingdom, 12Centre for Musculoskeletal Research, University of Manchester, Manchester, United Kingdom, 13Rheumatology Unit, Department of Medicine, Karolinska University Hospital in Solna, Karolinska Institutet, Stockholm, Sweden, 14Dermatology, Stanford University, Redwood City, CA, 15Centre for Rheumatology Research, Arthritis Research UK Centre for Adolescent Rheumatology, University College London, London, United Kingdom, 16NIAMS, NIH, Bethesda, MD, 17Neurology and Medicine, Johns Hopkins University, Baltimore, MD, 18Department of Neurology, Academic Medical Centre, Amsterdam, Netherlands, 19Rheumatology Division, Mayo Clinic, Rochester, MN, 20Institute of Rheumatology, University of Debrecen, Hungary, Debrecen, Hungary, 21Pediatria II, Reumatologia, PRINTO, IRCCS Istituto G. Gaslini, Genova, Italy, 22University of Pittsburgh, Pittsburgh, PA, 23Institute of Rheumatology, Charles University, Prague, Czech Republic

    Background/Purpose: To develop consensus on definitions of improvement (DOIs) for minimal and moderate improvement (and draft preliminary criteria for major improvement) in adult dermatomyositis (DM)…
  • Abstract Number: 367 • 2014 ACR/ARHP Annual Meeting

    In Early Rheumatoid Arthritis Patients with Non-Response to Methotrexate Monotherapy the Change in Multi-Biomarker Disease Activity Score Is Differentially Associated with Subsequent Response to Non-Biological Versus Biological Therapy

    Karen Hambardzumyan1, R.J. Bolce2, Saedis Saevarsdottir3, Kristina Forslind4, Ingemar F. Petersson5, Pierre Geborek6, Eric H. Sasso2, David Chernoff2, Scott Cruickshank7 and Ronald F. van Vollenhoven8, 1ClinTRID, the Karolinska Institute, Stockholm, Sweden, 2Crescendo Bioscience Inc., South San Francisco, CA, 3Rheumatology Unit, Department of Medicine, Karolinska Institutet, Stockholm, Sweden, 4Department of Medicine, Karolinska Institute, Stockholm, Sweden, 5Lund University, Lund, Sweden, 6Section of Rheumatology, Department of Clinical Sciences Lund, Lund University, Lund, Sweden, 7Scott Cruickshank and Associates, Inc., Santa Barbara, CA, 8Unit for clinical therapy research (ClinTrid), Karolinska Institute, Stockholm, Sweden

    Background/Purpose For patients with early RA (eRA), methotrexate (MTX) is recommended as first-line treatment and in non-responders both the addition of conventional non-biological disease modifying…
  • Abstract Number: 2896 • 2014 ACR/ARHP Annual Meeting

    a Multi-Center Double-Blind, Randomized, Controlled Trial (db-RCT) to Evaluate the Effectiveness and Safety of Co-Administered Traumeel® (Tr14) and Zeel® (Ze14) Intra‑articular (IA) Injections Versus IA Placebo in Patients with Moderate-to-Severe Pain Associated with OA of the Knee

    Carlos Lozada1, Eve del Rio2, Donald Reitberg2, Robert Smith2, Charles Kahn3 and Roland W. Moskowitz4, 1Rheumatology, University of Miami Miller School of Medicine, Miami, FL, Miami, FL, 2Clinical Research, Rio Pharmaceutical Services, LLC, Bridgewater, NJ, 3South Florida Rheumatology, Hollywood, FL, 4Div of Rheum/Dept of Medicine, University Hospitals Case Medical Center, Cleveland, OH

    Background/Purpose: Tr14 & Ze14 is a combination of dilute biological and mineral extracts administered IA for painful knee OA.  In response to clinician impressions of…
  • Abstract Number: 378 • 2014 ACR/ARHP Annual Meeting

    The Use of Week 12 CDAI, RAPID3 and DAS28(CRP) Responses to Predict Optimal Response to Methotrexate

    Gerd Burmester1, Gurjit S. Kaeley2, Jeffrey R. Curtis3, Yusuf Yazici4, Benoit Guerette5, Xin Wang5, Alan Friedman5 and Vibeke Strand6, 1Department of Rheumatology and Clinical Immunology, Charité University Medicine, Berlin, Germany, 2College of Medicine, University of Florida, Jacksonville, FL, 3University of Alabama at Birmingham, Birmingham, AL, 4Department of Medicine, Division of Rheumatology, New York University School of Medicine, New York, NY, 5AbbVie, Inc., North Chicago, IL, 6Adjunct, Division of Immunology / Rheumatology, Stanford University, Palo Alto, CA

    Background/Purpose The prediction of treatment outcomes based on early response could guide treatment decisions in patients (pts) with rheumatoid arthritis (RA). The objective was to…
  • Abstract Number: 2890 • 2014 ACR/ARHP Annual Meeting

    Does a Family History of RA Influence the Clinical Presentation and Treatment Response in RA?

    Thomas Frisell1, Saedis Saevarsdottir2,3 and Johan Askling1,4, 1Clinical Epidemiology Unit, Dept of Medicine, Karolinska Institutet, Stockholm, Sweden, 2Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden, 3Rheumatology Unit, Dept. of Medicine, Karolinska University Hospital and Karolinska Institutet, Stockholm, Sweden, 4Rheumatology Unit, Karolinska University Hospital, Stockholm, Sweden

    Background/Purpose: Since family history of RA is among the strongest risk factors for developing the disease, individuals suspected to have RA are routinely asked about…
  • Abstract Number: 2838 • 2014 ACR/ARHP Annual Meeting

    Exploratory Analysis of Pharmacokinetic Effects of Atacicept in Patients with Moderate to Severe Systemic Lupus Erythematosus

    David Wofsy1, Caroline Gordon2, Yong Li3, Stephen D. Wax4 and David Isenberg5, 1Division of Rheumatology, University of California, San Francisco, CA, 2Rheumatology Research Group, School of Immunity and Infection, College of Medical and Dental Sciences, University of Birmingham, Birmingham, United Kingdom, 3R&D Global BioStatistics, EMD Serono, Billerica, MA, 4Global Clinical Development Center - Immunology, EMD Serono Inc, Rockland, MA, 5Centre for Rheumatology Research, University College Hospital London, London, United Kingdom

    Background/Purpose: Atacicept is a fusion protein that inhibits B-cell stimulating factors BLyS and APRIL. We previously reported the clinical effects of atacicept in lupus patients…
  • Abstract Number: 2522 • 2014 ACR/ARHP Annual Meeting

    Effect of Infliximab Dose Increase in Rheumatoid Arthritis at Different Trough Concentrations

    Alejandro Balsa1, Chamaida Plasencia-Rodriguez2, Maria Gema Bonilla3, Alejandro Villalba2, Diana Peiteado2, Sara Garcia-Carazo4, Laura Nuño5, Teresa Jurado6, Emilio Martín-Mola7 and Dora Pascual-Salcedo8, 1Rheumatology, Hospital La Paz-IdiPaz, Madrid, Spain, 2Rheumatology, Hospital La Paz - IdiPaz, Madrid, Spain, 3Rheumatology Unit, La Paz University Hospital, Madrid, Spain, 4Rheumatology, Hospital La Paz-Idipaz, Madrid, Spain, 5Hospital La Paz-IdiPaz, Madrid, Spain, 6Immunology, La Paz University Hospital-Idipaz, Madrid, Spain, 7Rheumatology, Hospital Universitario La Paz, Madrid, Spain, 8Immunology, La Paz University Hospital, Madrid, Spain

    Background/Purpose To evaluate the effects of infliximab (Ifx) dose increase in active rheumatoid arthritis (RA) patients, presenting different serum infliximab concentrations.Methods Retrospective study including 42…
  • Abstract Number: 2515 • 2014 ACR/ARHP Annual Meeting

    Serum Survivin in Early Rheumatoid Arthritis

    Adrian Levitsky1, Malin Erlandsson2, Maria Bokarewa2 and Ronald F. van Vollenhoven3, 1The Karolinska Institute,Unit for Clinical Therapy Research, Inflammatory Diseases (ClinTRID), Stockholm, Sweden, 2Rheumatology and Inflammation Research, University of Gothenburg, Gothenburg, Sweden, 3Unit for Clinical Therapy Research, Inflammatory Diseases (ClinTRID), the Karolinska Institute, Stockholm, Sweden

    Background/Purpose: The proto-oncogene survivin regulates cell division and inhibits apoptosis. Elevated levels may be found in patients with rheumatoid arthritis (RA) and their presence has…
  • Abstract Number: 1789 • 2013 ACR/ARHP Annual Meeting

    In Early Rheumatoid Arthritis, The 12 Individual Biomarkers That Comprise The Multiple Biomarker Disease Activity Score Relate Differentially To Clinical Response and Radiographic Progression: Results From a Randomized Trial

    Karen Hambardzumyan1, Saedis Saevarsdottir2, Rebecca Bolce3, Kristina Forslind4, Sofia Ernestam5, Ingemar F. Petersson6, Pierre Geborek7, David Chernoff3, Douglas J. Haney3, Eric H. Sasso3 and Ronald F van Vollenhoven8, 1ClinTRID, the Karolinska Institute, Stockholm, Sweden, 2Karolinska Institutet, Stockholm, Sweden, 3Crescendo Bioscience Inc., South San Francisco, CA, 4Department of Medicine, Karolinska Institute, Stockholm, Department of Medicine, Karolinska Institute,, Stockholm, Sweden, 5Huddinge Hospital, Karolinska University Hospital, Huddinge, Sweden, 6Lund University, Lund, Sweden, 7Section of Rheumatology, Department of Clinical Sciences Lund, Lund University, Lund, Sweden, 8ClinTRID, Department of Medicine, Karolinska Institutet, Stockholm, Sweden

    Background/Purpose: In early rheumatoid arthritis (eRA), clinical and radiographic predictors would be very useful for optimizing available therapies. Individual biomarkers and their combinations, such as…
  • Abstract Number: 1451 • 2013 ACR/ARHP Annual Meeting

    Comparison Of Clinical Characteristics Of Patients With Rheumatoid Arthritis Receiving Their First Biologic and Biologic-Naïve Patients Considered Biologic-Suitable In The United States

    Siva Narayanan1, Yao Lu2, Richard Hutchings2 and Amanda Baskett2, 1Evidence Generation, Value and Access Center, Ipsos Healthcare, Columbia, MD, 2Ipsos Healthcare, London, United Kingdom

    Background/Purpose: Data on clinical status of biologic-naïve Rheumatoid Arthritis (RA) patients who are considered suitable for biologic therapy (by their physicians) is lacking. We assessed…
  • Abstract Number: 1423 • 2013 ACR/ARHP Annual Meeting

    The Influence Of Body Mass Index On The Efficacy Of Tumor Necrosis Factor Blocking Therapy For Rheumatoid Arthritis

    Ingrid M. Visman1, Inge A.M. van den Oever1, Charlotte L. M. Krieckaert1, Gertjan Wolbink1 and Michael T. Nurmohamed2, 1Rheumatology, Jan van Breemen Research Institute | Reade, Amsterdam, Netherlands, 2VU University Medical Center & Jan van Breemen Research Institute, Amsterdam, Netherlands

    Background/Purpose : The impact of Body mass Index (BMI) on efficacy of TNF blocking therapy is an important question, as adipose tissue appears to have…
  • Abstract Number: 1352 • 2013 ACR/ARHP Annual Meeting

    What Factors Lead To Achieve and Sustain Remission In Rheumatoid Arthritis Patients With Moderate To High Disease Activity?

    Soo-Kyung Cho1,2, Yoon-Kyoung Sung1,2, Jeeseon Shim3, Chan-Bum Choi4,5, Jung-Yoon Choe6, Won Tae Chung7, Seung-Jae Hong8, Jae-Bum Jun5, Tae-Hwan Kim9, Tae-Jong Kim10, Eun-Mi Koh11, Jisoo Lee12, Shin-Seok Lee10, Sung Won Lee13, Dae-Hyun Yoo5 and Sang-Cheol Bae1,2, 1Department of Rheumatology, Hanyang University Hospital for Rheumatic Diseases, Seoul, South Korea, 2Department of Rheumatology, Clinical Research Center for Rheumatoid Arthritis (CRCRA), Seoul, South Korea, 3Clinical Research Center for Rheumatoid Arthritis (CRCRA), Seoul, South Korea, 4Department of Rheumatology, Hanyang University Hospital for Rheumatic Diseases, Clinical Research Center for Rheumatoid Arthritis (CRCRA), Seoul, South Korea, 5Rheumatology, Hanyang University Hospital for Rheumatic Diseases, Seoul, South Korea, 6Catholic University of Daegu School of Medicine, Daegu, South Korea, 7Division of Rheumatology, Department of Internal Medicine, Dong-A University Hospital, Busan, South Korea, 8Division of Rheumatology, Department of Internal Medicine, Kyung Hee University, Seoul, South Korea, 9Division of Rheumatology, Department of Internal Medicine, Hanyang University Hospital for Rheumatic Diseases, Seoul, South Korea, 10Rheumatology, Chonnam National University Medical School and Hospital, Gwangju, South Korea, 11Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea, 12Internal Medicine, Ewha Womans University Mokdong Hospital, Seoul, South Korea, 13Rheumatology, Dong-A University Hospital, Busan, South Korea

    Background/Purpose: Clinical remission has now become the treatment goal in rheumatoid arthritis (RA), but it is not common in clinical practice. This study aimed to…
  • Abstract Number: 1312 • 2013 ACR/ARHP Annual Meeting

    A Multi-Biomarker Disease Activity Score Correlates With Radiographic Progression In Early Rheumatoid Arthritis: Results From a Randomized  Trial

    Karen Hambardzumyan1, Rebecca Bolce2, Scott E. Cruickshank3, Eric H. Sasso2, David Chernoff2, Kristina Forslind4, Saedis Saevarsdottir5, Ingemar F. Petersson6, Pierre Geborek7, Sofia Ernestam8 and Ronald F van Vollenhoven9, 1ClinTRID, the Karolinska Institute, Stockholm, Sweden, 2Crescendo Bioscience Inc., South San Francisco, CA, 3Scott E. Cruickshank and Associates, Inc., Santa Barbara, CA, 4Department of Medicine, Karolinska Institute, Stockholm, Department of Medicine, Karolinska Institute,, Stockholm, Sweden, 5Karolinska Institutet, Stockholm, Sweden, 6Lund University, Lund, Sweden, 7Section of Rheumatology, Department of Clinical Sciences Lund, Lund University, Lund, Sweden, 8Huddinge Hospital, Karolinska University Hospital, Huddinge, Sweden, 9ClinTRID, Department of Medicine, Karolinska Institutet, Stockholm, Sweden

    Background/Purpose: In early rheumatoid arthritis (eRA), predictors of radiographic damage would be useful for optimal targeting of therapy.  It has been suggested that combining various…
  • Abstract Number: 876 • 2013 ACR/ARHP Annual Meeting

    Prediction Of TNF Inhibitor Response In Rheumatoid Arthritis Patients Using Single Cell Network Profiling Of Intracellular Immune Signaling

    Jason Ptacek1, Rachael Hawtin2, Brent Louie1, Erik Evensen1, James Cordeiro1, Barbara Mittleman1, Michelle Atallah1, Alessandra Cesano2, Clifton O. Bingham III3, Stacey Cofield4, Jeffrey R. Curtis5, Maria I. Danila4, Richard A. Furie6, MC Genovese7, Marc C. Levesque8, Larry W. Moreland8, Peter A. Nigrovic9, James R. O'Dell10, William H. Robinson11, Nancy A. Shadick9, E. William St Clair12, Christopher C. Striebich13, Geoffrey M Thiele14, Peter K. Gregersen6 and S. Louis Bridges Jr.4, 1Nodality, Inc., South San Francisco, CA, 2Nodality Inc., South San Francisco, CA, 3Rheumatology, Johns Hopkins University, Baltimore, MD, 4University of Alabama at Birmingham, Birmingham, AL, 5Division of Clinical Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, AL, 6The Feinstein Institute for Medical Research and North Shore-Long Island Jewish Health System, Lake Success, NY, 7Stanford University, Palo Alto, CA, 8University of Pittsburgh, Pittsburgh, PA, 9Brigham and Women's Hospital/Harvard University, Cambridge, MA, 10Veteran Affairs Nebraska Western Iowa Health Care System and University of Nebraska Medical Center, Omaha, NE, 11VA Palo Alto Health Care System and Stanford University, Palo Alto, CA, 12Medicine, Duke Unversity Medical Center, Durham, NC, 13University of Colorado Denver, Aurora, CO, 14Omaha VA and the University of Nebraska Medical Center, Omaha, NE

    Background/Purpose:   Biomarkers predictive of drug efficacy are lacking in rheumatoid arthritis (RA) and would be useful in clinical practice and clinical trials.  Single cell…
  • Abstract Number: 790 • 2013 ACR/ARHP Annual Meeting

    Predictors and Sustainability Of Clinical Inactive Disease In Polyarticular Juvenile Idiopathic Arthritis Given Aggressive Therapy Very Early In The Disease Course

    Carol A. Wallace1, Edward H. Giannini2, Steven J. Spalding3, Philip J. Hashkes4, Kathleen M. O'Neil5, Andrew S. Zeft6, Ilona S. Szer7, Sarah Ringold8, Hermine Brunner9, Laura E. Schanberg10, Robert P. Sundel11, Diana Milojevic12, Marilynn G. Punaro13, Peter Chira14, Beth S. Gottlieb15, Gloria C. Higgins16, Norman T. Ilowite17, Yukiko Kimura18, Anne Johnson9, Bin Huang19 and Daniel J. Lovell2, 1University of Washington School of Medicine and Seattle Children's Hospital, Seattle, WA, 2Rheumatology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, 3Pediatric Institute, Department of Pediatric Rheumatology, The Cleveland Clinic, Cleveland, OH, 4Pediatrics, Shaare-Zedek Medical Center, Jerusalem, Israel, 5Pediatric Rheumatology, Riley Hospital for Children, Indianapolis, IN, 6Pediatric Institute, Department of Pediatric Rheumatology, Cleveland Clinic Foundation, Cleveland, OH, 7Div of Rheumatology, Rady Childrens Hosp San Diego, San Diego, CA, 8Pediatrics, Seattle Children's Hospital/Univ of Washington, Seattle, WA, 9Pediatric Rheumatology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, 10Pediatrics, Duke University Medical Center, Durham, NC, 11Division of Immunology, Boston Children's Hospital, Boston, MA, 12Dept of Pediatric Rheumatology, University of California, San Francisco, San Francisco, CA, 13Pediatric Rheumatology, Texas Scottish Rite Hospital, Dallas, TX, 14Pediatric Rheumatology, Indiana University School of Medicine, Riley Hospital for Children, Indianapolis, IN, 15Pediatric Rheumatology, Cohen Children's Medical Center of New York, New Hyde Park, NY, 16Pediatric Rheumatology Ohio State University, Nationwide Childrens Hosp, Columbus, OH, 17Pediatrics, The Children's Hospital at Montefiore, Bronx, NY, 18Pediatric Rheumatology, Joseph M Sanzari Children’s Hospital, Hackensack University Medical Center, Hackensack, NJ, 19Biostatistics and Epidemiology, Cincinnati Children's Hospital Medical Center/University of Cincinnati School of Medicine, Cincinnati, OH

    Background/Purpose: The double-blind, randomized placebo-controlled Trial of Early Aggressive Therapy in Polyarticular Juvenile Idiopathic Arthritis (TREAT) compared the ability of 2 aggressive treatment regimens to…
  • « Previous Page
  • 1
  • …
  • 4
  • 5
  • 6
  • 7
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

ACR Abstract Embargo Policy

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until Saturday, November 11, 2023.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying financial and other sponsors about this policy. If you have questions about the abstract embargo policy, please contact the public relations department at [email protected].

Copyright Policy

View ACR Policies.

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology